Show simple item record

Antiadenovirus drug discovery: potential targets and evaluation methodologies.

dc.contributor.authorSánchez-Céspedes, Javier
dc.contributor.authorSerna-Gallego, Ana
dc.contributor.authorMartínez Aguado, Pablo
dc.contributor.authorMarrugal-Lorenzo, Jose Antonio
dc.contributor.authorGómez-Marín, Isabel
dc.date.accessioned2026-01-26T13:19:47Z
dc.date.available2026-01-26T13:19:47Z
dc.date.issued2015-10-01
dc.identifier.citationMartínez-Aguado P, Serna-Gallego A, Marrugal-Lorenzo JA, Gómez-Marín I, Sánchez-Céspedes J. Antiadenovirus drug discovery: potential targets and evaluation methodologies. Drug Discov Today. 2015 Oct;20(10):1235-42. doi: 10.1016/j.drudis.2015.07.007. Epub 2015 Jul 23. PMID: 26210958.es
dc.identifier.issn1359-6446
dc.identifier.urihttps://hdl.handle.net/20.500.12412/7055
dc.description.abstractHuman adenoviruses (HAdV) are the cause of many acute infections, mostly in the respiratory and gastrointestinal (GI) tracts, as well as conjunctivitis. HAdV diseases in immunocompetent individuals are mostly self-limiting; however, in immunocompromised individuals, especially in pediatric units, HAdV infections are the cause of high morbidity and mortality. Despite the significant clinical impact, there are currently no approved antiviral therapies for HAdV infections. Here, we provide an overview of the different targets that could be considered for the design of specific drugs against HAdV, as well as the available in vitro and in vivo tools for the screening and evaluation of candidate molecules.es
dc.language.isoenges
dc.titleAntiadenovirus drug discovery: potential targets and evaluation methodologies.es
dc.typearticlees
dc.identifier.doi10.1016/j.drudis.2015.07.007
dc.issue.number10es
dc.journal.titleDrug Discovery Todayes
dc.page.initial1235es
dc.page.final1242es
dc.rights.accessRightsopenAccesses
dc.volume.number20es


Files in this item

This item appears in the following Collection(s)

Show simple item record